Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637343 | 0.99 | ADAMTS4 (0.37) | ADAMTS4MMP8ADAMTS5MGLLFAAH | |
| SCHEMBL636929 | 0.92 | ADAMTS4 (0.38) | ADAMTS4MMP8ADAMTS5MGLLFAAH | |
| SCHEMBL637174 | 0.90 | EPHX2 (0.37) | ADAMTS4MMP8ADAMTS5FAAHEPHX2 | |
| SCHEMBL916413 | 0.89 | EPHX2 (0.36) | ADAMTS4MMP8ADAMTS5FAAHEPHX2 | |
| SCHEMBL2231234 | 0.82 | KMT2A (0.41) | MGLLBCHELIPE | |
| SCHEMBL2231583 | 0.81 | KMT2A (0.41) | MGLLBCHELIPE | |
| SCHEMBL637975 | 0.81 | KMT2A (0.40) | MGLLBCHELIPE | |
| SCHEMBL915583 | 0.81 | KMT2A (0.40) | MGLLBCHELIPE | |
| SCHEMBL637841 | 0.81 | KMT2A (0.40) | MGLLBCHELIPE | |
| SCHEMBL917319 | 0.80 | MGLL (0.39) | MGLLBCHELIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | XENOPORT, INC. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | APEH, ABAT, GABARAPL1 | ADAMTS4 1675/4885MMP8 2694/4885ADAMTS5 1800/4885 |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | ADAMTS4 1643/4885MMP8 2860/4885ADAMTS5 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.